'''Mexazolam'''<ref>DE Patent 1954065</ref> (marketed under the trade names '''Melex''' and '''Sedoxil''')<ref>{{cite web|url=http://www.non-benzodiazepines.org.uk/benzodiazepine-names.html |title=Benzodiazepine Names |accessdate=2009-04-05 |publisher=non-benzodiazepines.org.uk |deadurl=yes |archiveurl=https://web.archive.org/web/20081208054743/http://www.non-benzodiazepines.org.uk/benzodiazepine-names.html |archivedate=2008-12-08 |df= }}</ref> is a drug which is a [[benzodiazepine]] derivative.<ref>{{cite journal |pmid=2893667 |year=1987 |last1=Kurono |first1=Y |last2=Kamiya |last3=Kuwayama |last4=Jinno |last5=Yashiro |last6=Ikeda |title=Kinetics and mechanism of the acid-base equilibrium of mexazolam and comparison with those of other commercial benzodiazepinooxazole drugs |volume=35 |issue=9 |pages=3831–7 |journal=Chemical & pharmaceutical bulletin |first2=K |first3=T |first4=Y |first5=T |first6=K |doi=10.1248/cpb.35.3831}}</ref>  Mexazolam has been trialed for anxiety and was found to be effective in alleviating anxiety at one week follow-up, however, after three weeks of therapy mexazolam had lost its therapeutic anxiolytic properties becoming no more effective than [[placebo]], presumably due to [[benzodiazepine tolerance]].<ref>{{cite journal |pmid=17535036 |year=2003 |last1=Ferreira |first1=L |last2=Figueira |last3=Bessa-Peixoto |last4=Marieiro |last5=Albuquerque |last6=Paz |last7=Cerqueira |last8=Damião |last9=Dolgner |title=Psychomotor and anxiolytic effects of mexazolam in patients with generalised anxiety disorder |volume=23 |issue=4 |pages=235–43 |journal=Clinical drug investigation |doi=10.2165/00044011-200323040-00003 |first2=ML |first3=A |first4=A |first5=R |first6=C |first7=A |first8=P |first9=A |last10=Dingemanse |first10=Jasper |display-authors=8 }}</ref> Mexazolam is metabolised via the [[CYP3A4]] pathway. [[HMG-CoA reductase inhibitors]] including [[simvastatin]], [[simvastatin acid]], [[lovastatin]], [[fluvastatin]], [[atorvastatin]] and [[cerivastatin]] inhibit the metabolism of mexazolam,<ref>{{cite journal |pmid=12911366 |year=2003 |last1=Mc Donnell |first1=CG |last2=Harte |last3=O'driscoll |last4=O'loughlin |last5=Van Pelt |last6=Shorten |title=The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam |volume=58 |issue=9 |pages=899–904 |journal=Anaesthesia |doi=10.1046/j.1365-2044.2003.03339.x |first2=S |first3=J |first4=C |first5=FN |first6=GD }}</ref> but not the HMG-CoA reductase inhibitor [[pravastatin]].<ref>{{cite journal |pmid=12124308 |url=http://dmd.aspetjournals.org/cgi/content/full/30/8/904 |doi=10.1124/dmd.30.8.904 |year=2002 |last1=Ishigami |first1=M |last2=Takasaki |last3=Ikeda |last4=Komai |last5=Ito |last6=Sugiyama |title=Sex difference in inhibition of in vitro mexazolam metabolism by various 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors in rat liver microsomes. |volume=30 |issue=8 |pages=904–10 |journal=Drug metabolism and disposition: the biological fate of chemicals |first2=W |first3=T |first4=T |first5=K |first6=Y }}</ref><ref>{{cite journal |pmid=11181496 |url=http://dmd.aspetjournals.org/cgi/content/full/29/3/282 |journal=Drug Metabolism and Disposition |title=A Comparison of the Effects of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors on the CYP3A4-Dependent Oxidation of Mexazolam in Vitro |volume=29 |issue=3 |pages=282–8 |year=2001 |author1=Ishigami, Michi |author2=Honda, Tomoyo |author3=Takasaki, Wataru |author4=Ikeda, Toshihiko |author5=Komai, Toru |author6=Ito, Kiyomi |author7=Sugiyama, Yuichi }}</ref>
